Neukio Bio of Shanghai Raises $40 Million for Universal CAR-T Therapies

Neukio Biotherapeutics, a Shanghai startup, completed a $40 million Angel round to develop universal CAR-T therapies. The round was led by Lilly Asia Venture, with participation from IDG Capital and Sherpa Investments. Neukio is developing allogenic cell therapies from the iPSC-CAR-NK axis. The company combines in-house innovation and external collaboration with global partners. Dr. Richard Wang, Founder, Chairman and CEO of Neukio was previously CEO of Fosun Kite, where he oversaw China development of Kite's Yescarta, an autologous CAR-T therapy. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.